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Abstract
There is need for improved human influenza vaccines, particularly for older adults who are at greatest risk for severe disease,
as well as to address the continuous antigenic drift within circulating human subtypes of influenza virus. We have
engineered an influenza virus-like particle (VLP) as a new generation vaccine candidate purified from the supernatants of Sf9
insect cells following infection by recombinant baculoviruses to express three influenza virus proteins, hemagglutinin (HA),
neuraminidase (NA), and matrix 1 (M1). In this study, a seasonal trivalent VLP vaccine (TVV) formulation, composed of
influenza A H1N1 and H3N2 and influenza B VLPs, was evaluated in mice and ferrets for the ability to elicit antigen-specific
immune responses. Animals vaccinated with the TVV formulation had hemagglutination-inhibition (HAI) antibody titers
against all three homologous influenza virus strains, as well as HAI antibodies against a panel of heterologous influenza
viruses. HAI titers elicited by the TVV were statistically similar to HAI titers elicited in animals vaccinated with the
corresponding monovalent VLP. Mice vaccinated with the TVV had higher level of influenza specific CD8+ T cell responses
than a commercial trivalent inactivated vaccine (TIV). Ferrets vaccinated with the highest dose of the VLP vaccine and then
challenged with the homologous H3N2 virus had the lowest titers of replicating virus in nasal washes and showed no signs
of disease. Overall, a trivalent VLP vaccine elicits a broad array of immunity and can protect against influenza virus challenge.
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Introduction
The influenza A virus, a member of the Orthomyxoviridae family,
is an enveloped segmented, negative-strand RNA virus with a
genome consisting of eight individual genes that encode at least ten
proteins [1]. Influenza A viruses are further subdivided by
antigenic characterization of the hemagglutinin (HA) and
neuraminidase (NA) surface glycoproteins. Currently, there are
16 identified HA and 9 NA subtypes [2]. Waterfowl, such as ducks
and geese, serve as a natural reservoir for all known subtypes of
influenza A virus [3]. Annually, human outbreaks of influenza
types A subtypes, currently H1N1 and H3N2 and influenza B are
responsible for substantial morbidity and mortality in humans [4].
High-risk groups, such as elderly, infants, and immunocompro-
mised individuals are most susceptible to infection and severe
disease.
Prevention is the most effective method of reducing transmission
of influenza [5] and protection is primarily mediated by antibodies
to the HA and NA (see reviews [6,7]. The HA is responsible for
attachment of the virus to human epithelial cells that line the
upper respiratory tract as well as fusion of the viral and cellular
lipid membranes during initial stages of infection. The NA has
enzymatic properties that are associated with the release of nascent
virions from cell membranes following viral replication [8].
Annual influenza epidemic and periodic pandemic outbreaks
result from continuous antigenic changes within HA and NA
proteins, known as antigenic drift and shift. During antigenic drift,
HA and NA surface antigens undergo progressive amino acid
substitutions that can result in evasion of the previously acquired
immunity. Therefore, currently licensed influenza vaccines can
vary widely in their level of efficacy from year to year due to
selection of a vaccine strain does not sufficiently match the
circulating virus strain within a population. Surveillance within
avian and human populations is a cornerstone of the World
Health Organization’s influenza surveillance network which each
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humans throughout the northern and southern hemisphere and
convenes bi-annually to recommend new influenza strains believed
to be suitable for subsequent annual vaccine manufacture based
on epidemiological and antigenic considerations and their
anticipated prevalence during the coming season [9].
Traditionally, inactivated whole, split or purified influenza A
and B virus vaccines are prepared by culturing live virus in
embryonated chicken eggs. There are limitations to relying on an
egg-based manufacturing system including egg allergies in a small
percentage of the population as well as potential issues with egg
supply for surge capacity or potential depletion of egg supply due
to avian influenza outbreaks. Alternative influenza vaccine
manufacturing platforms based upon scalable and recombinant
approaches could therefore be of great public benefit.
Recently, we have described the development of influenza A
H3N2, H5N1, and H9N2 VLP vaccine candidates that were
comprised of three influenza virus structural proteins, HA, NA,
and M1 and expressed from insect cells [10–13] and others have
described similar VLPs based upon a lentiviral core [14]. This new
generation vaccine candidate has potential advantages over
current egg-based methods, particularly for immunogenicity and
high-yielding, inexpensive production. In this study, VLP vaccines
were constructed for a seasonal trivalent vaccine using isolates
from influenza A H1N1 (A/New Caledonia/20/1999), H3N2 (A/
New York/55/2004), and influenza B (B/Shanghai/367/2002) to
match strains recommended for the commercially marketed
seasonal 2005–2006 Northern Hemisphere vaccine formulation.
This investigational seasonal influenza vaccine is composed of
non-infectious, non-replicating VLPs that exhibit functional HA
and NA properties. These vaccines were tested in both mice and
ferrets for the induction of immune responses that correlate with
protection and these elicited immune responses were compared to
immune responses elicited from the corresponding monovalent
VLP in the same animal study. In addition, immune responses
elicited in mice by the TVV and by the commercial TIV were
compared.
Materials and Methods
Cloning of HA, NA, and M1 genes and the generation of
recombinant baculoviruses
Abbreviations for the H3N2 viral isolates or proteins used in this
study were: A/Brisbane/10/2007 (Bris/10/07), A/Wisconsin/67/
2005 (Wisc/05), A/New York/55/2004 (NY/04), A/Wyoming/
4/2003 (Wyo/03), Fujian/411/2002 (Fuj/02), A/Panama/2007/
99 (Pan/99), A/Aichi/2/1968 (Aichi/68). Abbreviations for the
H1N1 viral isolates or proteins used in this study were: A/
Brisbane/59/2007 (Bris/59/07), A/Solomon Island/3/2006 (SI/
06), A/New Caledonia/20/1999 (NC/99), A/Puerto Rico/8/
1934 (PR/8/34). Abbreviations for influenza B viruses or proteins
used in this study were B/Florida/4/2007 (B/FL/07), B/
Malaysia/2506/2004 (B/May/04), B/Shanghai/361/2002 (B/
Shang/02), B/Sichuan/379/99 (B/Sich/99). Influenza VLPs
representing NY/04, NC/99, B/Shang/02 were constructed
and purified from a baculovirus/insect cell expression system as
previously described [11,13]. Particle production was analyzed by
sucrose gradient ultracentrifugation and chromatography followed
by Western blot as described [11].
Comparative antigens and controls
Wyo/03 virus was inactivated using 0.1% Formalin (Center for
Biological Evaluation and Research (CBER), Food and Drug
Administration (FDA), Rockville, MD, USA) and rHA (Lot # 45-
04028) derived from Wyo/03 virus was purified from the
supernatants of Sf9 insect cells following baculovirus infection
(Protein Sciences Corp., Meriden, CT, USA). The previously
described the HIV-1 VLP [15], expressed from the HIV-1NL4-3
Gag plasmid was used as a negative viral particle control in this
study. 2007–2008 commercial trivalent split FLUARIX (Glax-
oSmithKline, Research Triangle Park, NC, USA) vaccine was
used as a comparator control.
Animals and vaccinations
BALB/c mice (Mus musculis, females, 6–8 weeks) were purchased
from Harlan Sprague Dawley, (Indianapolis, IN, USA) and
housed in microisolator units and allowed free access to food
and water and were cared for under USDA guidelines for
laboratory animals. Mice (12–21 mice per group) were vaccinated
with purified VLPs (3 mg, 0.6 mg, or 0.12 mg), based upon HA
content from a SRID potency assay, via intramuscular injection at
week 0 and then boosted with the same dose at week 3. A subset of
mice was vaccinated with the FLUARIX TIV vaccine (TIV) at a
0.6 mg HA dose to match the dose of VLP vaccine. Blood was
collected from anesthetized mice via the orbit and transferred to a
microfuge tube. Tubes were centrifuged and sera was removed
and frozen at 28065uC. All procedures were in accordance with
the NRC Guide for the Care and Use of Laboratory Animals, the
Animal Welfare Act, and the CDC/NIH Biosafety in Microbio-
logical and Biomedical Laboratories.
Fitch ferrets (Mustela putorius furo, male, 6–12-months of age),
influenza naı ¨ve and descented were purchased from Marshall
Farms (Sayre, PA, USA). Ferrets were pair housed in stainless steel
cages (Shor-line, Kansas City, KS, USA) containing Sani-chips
Laboratory Animal Bedding (P.J. Murphy Forest Products,
Montville, NJ, USA). Ferrets were provided with Teklad Global
Ferret Diet (Harlan Teklad, Madison, WI, USA) and fresh water
ad libitum. Influenza VLPs were diluted in PBS, pH 7.2 to achieve
final concentration. Ferrets (n=6) were vaccinated with one of
three doses (15 mg, 3 mg, 0.6 mg) of purified VLPs (NY/04, NC/
99, and B/Shang/02 in monovalent or trivalent formulations) in
the left hind leg muscle in a volume of 0.5 ml. Vaccines were
stored at 4uC prior to use. Control animals were mock vaccinated
with an HIV-1 VLP (ADA strain) as a negative control. Animals
were monitored for weight loss, temperature, loss of activity, nasal
discharge, sneezing and diarrhea weekly during the vaccination
regimen and each day during viral challenge. Prior to vaccina-
tions, animals were confirmed by HAI assay to be seronegative for
circulating influenza A (H1N1 and H3N2) and influenza B viruses.
Blood was collected from anesthetized ferrets via the anterior
vena cava. Blood was transferred to a tube containing a serum
separator and clot activator and allowed to clot at room
temperature. Tubes were centrifuged and sera was removed and
frozen at 28065uC. All procedures were in accordance with the
NRC Guide for the Care and Use of Laboratory Animals, the
Animal Welfare Act, and the CDC/NIH Biosafety in Microbio-
logical and Biomedical Laboratories.
HAI antibody levels in sera
The hemagglutination inhibition (HAI) assay was adapted from
the CDC laboratory-based influenza surveillance manual (3). To
inactivate non-specific inhibitors, sera were treated with receptor
destroying enzyme (RDE) prior to being tested (6, 7). Briefly, three
parts RDE was added to one part sera and incubated overnight at
37uC. RDE was inactivated by incubation at 56uC for ,30 min
and then six parts of saline were added, creating a 1:8 dilution of
serum. RDE-treated sera were two-fold serially diluted in v-
bottom microtiter plates. An equal volume of virus, adjusted to
VLPs Elicit Immunity
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were covered and incubated at room temperature for 15 min
followed by the addition of 0.5% turkey erythrocytes (TRBC)
(Lampire Biologicals, Pipersville, PA, USA). The TRBCs were
adjusted with PBS to achieve a 0.5% vol/vol suspension. The cells
were stored at 4uC and used within 72 hours of preparation (2).
The plates were mixed by agitation, covered, and the TRBC were
allowed to settle for 30 min at room temperature. The HAI titer
was determined by the reciprocal dilution of the last well which
contained non-agglutinated TRBC. Positive and negative serum
controls were included for each plate. All mice and ferrets were
negative (HAI#10) for pre-existing antibodies to currently
circulating human influenza viruses prior to vaccination (1).
ELISPOT assays
Spleens and lung tissue were harvested from vaccinated mice at
day 6 post-challenge (day 41 of the study) and collected cells were
isolated for ELISPOT assays, as previously described [16,17].
Whole lungs or spleens were removed and forced into a single cell
suspension using a cell strainer (BD Biosciences, Bedford, MA,
USA) in a total volume of 4 ml. Red blood cells were then lysed
using 5 ml of ACK buffer (0.15 M NH4Cl, 10 mM KHCO3 and
0.1 mM Na2EDTA). The lung and spleen cells were then
resuspended in 1 ml and 3 ml, respectively, of RPMI medium
with 10% fetal bovine serum (cRPMI). Cell viability was
determined by trypan blue exclusion staining.
Briefly, splenocytes were depleted of erythrocytes by treatment
with ammonium chloride (0.1 M, pH 7.4). Following thorough
washing with PBS, cells were resuspended in RPMI medium with
10% fetal bovine serum (cRPMI). Cell viability was determined by
trypan blue exclusion staining. The number of anti-HA or anti-M1
specific murine IFN-c (mIFN-c) secreting splenocytes was
determined by enzyme-linked immunospot (ELISPOT) assay (R
& D Systems, Minneapolis, MN, USA). Briefly, pre-coated anti-
mIFN-c plates were incubated (25uC for 2 h) with cRPMI (200 ml)
and then were incubated with splenocytes or lung cells (5610
5/
well) isolated from vaccinated mice. Splenocytes or lung cells were
stimulated (48 h) with peptides (BEI Research Resources Repos-
itory, Manassas, VA, USA). For HA, six pools of peptides (15mers
overlapping by 11 amino acids) and for M1, four peptides pools
(15mers overlapping by 11 amino acids) from the A/New
Calendonia/20/1999 were used to stimulate cells. Additional
wells of cells were stimulated with PMA (50 ng)/ionomycin (500
ng) or were mock stimulated. In addition, IL-2 was added to all
wells (10 units/ml). Plates were washed with PBS-Tween (3X) and
were and were incubated overnight at 4C with anti-IFN-c
antibody. The plates were washed and then incubated (25uC for
2 h) with strepavidin conjugated to alkaline phosphatase. Follow-
ing extensive washing, cytokine/antibody complexes were incu-
bated (25uC for 1 h) with stable BCIP/NBT chromagen. The
plates were rinsed with dH2O and air dried (25uC for 2 h). Spots
were counted by an ImmunoSpot ELISPOT reader (Cellular
Technology Ltd., Cleveland, OH, USA).
Flow cytometry
A multi-parameter flow cytometry assay combining MHC class
I pentamer with intracellular cytokine staining was employed to
detect influenza specific CD8
+ T cells. The CD8
+ T cell responses
to nucleoprotein (NP) 147 (TYQRTRALV) are dominant followed
by hemagglutinin (HA) 533 (IYSTVASSL) responses in influenza-
virus-infected BALB/c mice. HA533 was originally described for
the HA of PR8 (H1N1) [18]. This epitope is conserved in H1N1
viruses. Lung lymphocytes and splenocytes of infected mice were
stimulated for 5 h with 1 mg/ml of HA533,N P 147,o ra n
ovalbumin Ova257 control peptide in the presence of the Golgi-
blocking agents brefeldin A and monensin. The cells were washed
with FACS buffer (PBS, 1% FBS, 0.1% sodium azide) and were
blocked with anti-CD16/CD32 mouse Fc receptor block (BD
Biosciences, San Jose, CA, USA), followed by staining with a
murine MHC-I encoded allele K
d-specific pentamer for the
immunodominant HA 533 epitope or NP147 epitope (ProImmune,
Oxford, UK) conjugated with phycoerythrin (PE). Lymphocytes
were then stained with anti-CD8 antibodies conjugated with
Pacific Blue and anti-CD19 antibodies conjugated with APC-Cy7
(BD Biosciences, San Jose, CA, USA). The cells are then incubated
with a viability dye (Molecular Probes, Invitrogen, Eugene, OR,
USA). Once the surface staining is complete the cells are fixed and
permeabilized with BD Cytofix/Cytoperm solution (BD Biosci-
ences, San Jose, CA, USA). The cells were washed in Perm/Wash
buffer (BD Biosciences, San Jose, CA, USA) and the intracellular
antibodies were added in Perm/Wash buffer. Cells were stained
intracellular with FITC conjugated anti-IL-2 (eBioscience, San
Diego, CA, USA), PE-Cy7 conjugated anti-IFN-c (BD Bioscienc-
es, San Jose, CA, USA) and Alexa Fluor 488H conjugated anti-
TNFa (eBiosciences, San Diego, CA, USA). Cells were fixed in
1% formalin/PBS and data acquired using a LSRII flow
cytometer (BD Biosciences, San Jose, CA, USA). The data were
analyzed with FlowJo software (Treestar, Ashlend, OR, USA).
Challenge with influenza virus
Mice were challenged intranasally with 7.25610
5 pfu of mouse-
adapted (ma) NC/99 (H1N1). Mice were monitored daily for
morbidity and body weights were recorded each day. Mice that
lost greater than 20% of body weight were euthanized. The ability
of each vaccine to protect against challenge was compared to
separate groups of mock vaccinated control mice that were
challenged with the virus.
Vaccinated ferrets were challenged intranasally with
5.0610
5 pfu of influenza NY/04 virus (H3N2). Nasal wash
samples were taken from ferrets on days 1, 3, and 5 post-challenge
and influenza virus was titrated in MDCK cells to determine virus
shedding in upper respiratory tissues [19]. Samples were collected,
snap frozen at 270uC and later thawed, homogenized in 1 ml of
cold PBS and pelleted by centrifugation. Clarified homogenates
were titrated in MDCK cells for virus infectivity from initial
dilutions of 1:10. The limit of virus detection was 1610
2 pfu/ml.
Statistical analysis
Statistical analyses were performed using the Student’s t-test.
Samples from VLP-vaccinated mice and ferrets were compared to
TIV-vaccinated or mock vaccinated mice and significance was
considered at a p-value ,0.05.
Results
Serum HAI antibody measurements following VLP
immunizations
Individual recombinant baculoviruses were used to infect Sf9
insect cells that subsequently expressed HA, NA, and M1 proteins
from either NC/99 (H1N1), NY/04 (H3N2), or B/Shang/02
strains of influenza virus to spontaneously form VLPs that were
then purified as previously described [11]. Immunogenicity of
VLPs was examined in BALB/c mice (6–8 weeks) inoculated by
intramuscular injection (i.m.) at 0 and 3 weeks with purified
monovalent (3 mg) or a trivalent mixtures (3 mg, 0.6 mg, 0.12 mg) of
the antigen (Fig. 1). Post-vaccination antisera were evaluated for
the ability to prevent virus-induced agglutination of turkey RBCs
(Fig. 2). These results were compared to mice vaccinated with the
VLPs Elicit Immunity
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dose, 75% of the mice vaccinated with 3 mg of the TVV had
measurable titers of HAI antibodies ($1:40) against the NC/99
(Fig. 2A) while forty-seven percent had HAI titers against NY/04
(Fig. 2C) and 100% of the mice had HAI titers against B/Shang/
02 (Fig. 2E). At week 5, following two vaccinations, all mice
immunized with the TVV at 3 mg had HAI titers against NC/99
(GMT 640), NY/04 (GMT 423) and B/Shang/02 (GMT 640).
Mice that were vaccinated with a 3 mg dose of each monovalent
VLP vaccine had HAI titers to homologous strains that were
statistically similar to the corresponding HAI titer elicited by the
TVV at the same dose (Fig. 2B, 2D, and 2F). All mice vaccinated
with monovalent VLPs had HAI titers $1:40. There was little, if
any, HAI cross-reactivity against viruses from non-corresponding
subtypes (data not shown). In contrast, 70–75% of the mice
vaccinated with TIV had HAI titers $1:40 to one of the three
homologous viruses (Fig. 2). In addition, mice vaccinated with
TVV had statistically higher HAI GMT compared to mice
vaccinated with TIV, regardless of influenza strain tested. For
NC/99 and B/Shang/02, HAI titers elicited in mice vaccinated
with 0.12 mg of TVV were statistically higher than mice
vaccinated with 3 mg of TIV. Therefore, in general, the TVV
was inducing higher HAI titers than the TIV, with broader cross-
protection.
Influenza virus challenge of TVV and TIV vaccinated mice
Mice vaccinated with H1N1 VLPs, the TVV, or the TIV were
challenged with a mouse-adapted NC/99 (ms-NC/99) (Fig. 3). We
had a limited number of mouse-adapted viruses to choose for these
studies. The NC/99 virus matched the H1N1 component in these
vaccines. HIV-1 VLP vaccinated mice challenged with virus
showed physical signs of infection (ruffled fur, dyspnea, lethargy)
and they lost 15–20% of their original body weight between days
4–6 post-challenge (Fig. 3). Sixty percent of these mice died by day
8 post-infection and the remaining mice recovered. Surprisingly,
mice vaccinated with the H1N1 VLP, TVV, or TIV and then
challenged with ma-NC/99 virus lost a similar amount of weight
as the mock control animals, but appeared to recover more quickly
(Fig. 3A). Even though, all vaccinated and mock-vaccinated mice
had similar high viral lung titers at day 3 post-challenge (Table 1),
all the mice vaccinated with the H1N1 VLP, TVV, or TIV
survived challenge. As a control, mice were vaccinated with a
mouse-adapted B influenza virus (ma-B/Sich/02) and all the
monovalent B, TVV and TIV mice showed no signs of weight loss
and had no outward signs of disease, had little or no B/Sich/02
virus detected in the lungs, whereas HIV-1 VLP vaccinated died
by day 6 post-infection (data now shown).
Cell-mediated immunity elicited by VLP vaccines
It was an unexpected finding that vaccinated mice, subsequently
challenged with the mouse-adapted NC/99 virus, lost ,15% of
their original body weight, since all the vaccines contained NC/99
HA and they both elicited high HAI titers against NC/99 virus
(Fig. 2). Therefore, we tested the antisera against the mouse-
adapted NC/99 virus used for challenge. Interestingly, there was
very low HAI activity against the mouse-adapted NC/99 virus
(Fig. 4A) and only 20% of the mice had titers $1:40, whereas all
the mice had high titers against the wild-type human NC/99 virus
(Fig. 2A). The vaccines contained the human sequences. The virus
was mouse-adapted. The HAI titers elicited by the TVV and TIV
Figure 1. Antibodies elicited by vaccination. Mice (n=8) were vaccinated via intramuscular injection at weeks 0 and 3 with VLPs representing a
H1N1 virus (NC/99), a H3N2 VLP (NY/04), or a B VLP (B/Shang/02) individually (3 ug) or in a trivalent mixture at one of three doses (3 mg, 600 ng, or
120 ng). A) Schematic of the vaccine regimen. B) Vaccines and doses administered.
doi:10.1371/journal.pone.0006032.g001
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10, we verified if the vaccines that contained the human NC/99
HA elicited HAI antibodies that recognized mouse-adapted NC/
99 HA. The number of differences in the mouse adapted HA and
the human HA are 12.
Viral infection and subsequent weight loss in vaccinated mice
challenged with ma-NC/99 virus provided an opportunity to
examine the cellular responses in these mice post-challenge, since
vaccinated mice did appear to recover more quickly from NC/99
virus infection than unvaccinated mice (Fig. 3A). Splenocytes and
lung cells were collected at day 6 post-challenge from mice
vaccinated with TVV, TIV, or mock control animals. At 6 day
post infection, the T cell response was low, unless there was
preexisting memory allowing for a quicker recall response.
Splenocytes were stimulated in vitro in an IFNc-ELISPOT assay
with 6 pools of overlapping peptides representing the HA protein
or with peptides stimulation CD8
+ T cells specific for the
immunodominant epitopes HA533 (IYSTVASSL) or NP147
(TYQRTRALV). In both H1N1 vaccine strains in the TVV and
TIV, the HA533 epitope is conserved in the HA protein and
therefore allows for direct comparison of the CD8
+ T cell
responses. As expected, mice vaccinated with the TIV had high
HAI titers against the three homologous viruses in the TIV (data
not shown). In contrast, HA-specific cellular responses were
elicited by the TVV, but not the TIV (Fig. 5). T cell responses
were directed against epitopes throughout the HA (pools 2, 3, 5,
Figure 2. Hemaggutination-inhibition (HAI) titers. Week 0, 3, and 5 serum HAI antibody responses were assessed against H1N1 (NC/99), H3N2
(NY/04), B, (B/Shang/02) viruses. Bars indicate geometric mean titer (GMT) +/2 SEM. Mice vaccinated with one of three doses of the TVV (A, C, E) or
each VLP individually; H1N1 VLP (B), H3N2 VLP (D), B VLP (F).
doi:10.1371/journal.pone.0006032.g002
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approximately 3 times the number of HA533 specific CD8
+ T
cells was detected in mice vaccinated with the TVV compared to
TIV-vaccinated mice (Fig. 5). As expected, CD8
+ T cells specific
for the NP147 epitope were only detected above background in
TIV vaccinated mice, since the VLP vaccines did not contain NP.
There were no differences in the number of low cellular responses
detected against M1 antigen (data not shown). In mice vaccinated
with VLPs, there were approximately twice as many HA533-
pentamer positive CD8
+ T cells in the lung compared to TIV
vaccinated mice, as shown by flow cytometry (Fig. 5B). Intracel-
lular cytokine staining for IFN-c revealed that approximately 6%
of CD8
+ T cells in the lungs of VLP vaccinated mice produce
IFNc after in vitro stimulation with the HA533 peptide (Fig. 5C),
which was significantly higher than in TIV-immunized mice (1%).
As expected, control mice had few HA-specific responses 6 days
post-challenge.
Influenza challenge of VLP vaccinated ferrets
To confirm the effectiveness of these VLP vaccines, ferrets were
vaccinated with 15 mg dose of the, monovalent H3N2 VLPs,
TVV, or TIV. At week 3, all ferrets vaccinated with the TVV had
high HAI titers against B/Shang/02, NC/99 and NY/04, albeit
lower titers than against the influenza B virus (data not shown).
The monovalent H3N2 VLP elicited similar titers after a single
vaccination at week 3 as the TVV against NY/04. At week 5, all
TVV vaccinated ferrets had HAI titers $1:40 against all three
viruses (NC/99, NY/04, B/Shang/02) in the vaccine (Fig. 6A).
The HAI GMT against NC/99 was 1:80, against NY/04 was
1:727, and against B/Shang/02 was 1:1280. Ferrets vaccinated
with 15 mg dose of the monovalent H3N2 VLP had HAI titers
against NY/04 (1:367), but no cross-reactive HAI antibodies
against NC/99 or B/Shang/02 (Fig. 6B). No ferrets vaccinated
with lower doses of TVV (3 mg or 0.6 mg) had HAI titer $1:40
against NC/99 or NY/04 (data not shown). The TVV elicited
little or no cross-reactive HAI antibodies against the closely related
SI/06 (H1N1) or B/May/04 viruses (Fig. 6A). However, both the
TVV and the monovalent H3N2 VLP elicited HAI antibodies in
50–67% of ferrets against related H3N2 viruses, Pan/99, Fuj/02,
Wisc/05, or Bris/10/07.
Ferrets were challenged intranasally with the H3N2 NY/04
virus (5610
5 pfu). HIV-1 VLP vaccinated ferrets showed clinical
signs of infection (lethargy), a spike in temperature (,2uC) in the
first 24 hours post-challenge, and an increase in virus was detected
in the nasal wash (8.25610
5 pfu/ml) (Fig. 7 and Table 2). Similar
viral titers were observed in ferrets vaccinated with a 0.6 mg dose
of TVV (1.57610
6 pfu/ml). However, there was a dose dependent
decrease in viral titers that correlated with increasing doses of
TVV. Ferrets vaccinated with 15 mg of TVV had similar viral
titers in the nasal wash as ferrets vaccinated with 15 mg of the
monovalent H3N2 VLP vaccine. In contrast, mice vaccinated with
15 mg of TIV had titers similar to the 15 mg of TVV. Viral titers
dropped precipitously by day 3 post-challenge and no viruses were
detected in the nasal wash after day 5 in any of the groups.
Discussion
Immune responses elicited by a trivalent mixture of influenza
virus-like particles expressing antigens from influenza A H1N1,
H3N2, and influenza B viruses were shown to elicit immune
responses in mice and ferrets as measured by serum HAI antibody
titers and protection following viral challenge. For human
influenza vaccinations, formalin-inactivated split virus that elicits
HAI antibody titers in the range of 1:40 are required to confer
Figure 3. Influenza virus challenge. At week 5, mock vaccinated
mice or mice vaccinated with vaccines (3 mg) were challenged
intranasally with the mouse-adapted influenza ma-NC/99 virus
(2.6610
5 pfu). Mice were monitored daily for weight loss, activity, and
survival. Body weight is plotted as percentage of the average initial
weight. Mice that lost greater than 20% body weight were sacrificed.
doi:10.1371/journal.pone.0006032.g003
Table 1. Virus titers in lungs of mice challenged with mouse-
adapted H1N1.
Vaccine
a Virus titer (pfu/ml) in lungs
NC/99 (H1N1)
TVV 2.3610e+5
H1N1 VLP 6.3610e+4
TIV 1.0610e+5
HIV-1 VLP 9.0610e+5
aVaccine administered at weeks 0 and 3.
doi:10.1371/journal.pone.0006032.t001
Figure 4. HAI titers against mouse-adapted viruses. Week 5
serum HAI antibody responses were assessed against ma-NC/99 virus.
Bars indicate geometric mean titer (GMT) +/2 SEM.
doi:10.1371/journal.pone.0006032.g004
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$1:40 are generally considered an immunological correlate of
protection threshold beyond which it is unlikely that serious illness
will occur [12,19]. Following two vaccinations with the TVV, all
mice and ferrets vaccinated with the highest doses of VLPs had
HAI titers $1:40 against the matched homologous viruses. Mice
vaccinated with the each monovalent VLP elicited HAI titers
against the homologous virus, whereas the TVV mixture elicited
immune responses against all three influenza viruses (Fig. 2). There
was a dose-dependent decline in the HAI titer in ferrets vaccinated
with lower doses of TVV. There was no significant loss in HAI
titer to a specific virus when the VLP was formulated in a trivalent
mixture compared to the same monovalent VLP little immune
interference or dominance of one VLP over others in the TVV.
HAI results from ferrets that were administered the same
trivalent and monovalent VLP vaccines showed similar results as
the mice against the homologous viruses to the vaccines (Fig. 6).
However, only 50% of ferrets vaccinated with the TVV or the
monovalent H3N2 VLP vaccine had cross-reactive HAI titers
against a panel of H3N2 viruses isolated from 1999–2007. None of
the ferrets had cross-reactivity against contemporary H1N1 viruses
and only modest levels of cross-reactive HAI antibodies against
influenza B viruses. Three of the ferrets had HAI titers $1:256
and only sera from these three ferrets reacted against other H3N2
viruses. Mice and ferrets vaccinated with TIV had average HAI
GMT greater than 1:40, however, these titers were generally lower
than those elicited by TVV.
Although HAI antibody titer is a generally accepted correlate of
protection against influenza, these VLPs were effective at eliciting
cellular responses, which may have contributed to protection or
hastened the recovery of infected animals compared to TIV-
vaccinated or mock vaccinated animals. Even though detection of
cellular responses was low and sporadic prior to challenge, the
induction of HA-specific, CD8
+ IFN-c secreting memory T cells
Figure 5. T cell responses. A. IFN-gamma ELISPOT. Splenocytes were collected on day 6 post-infection with mouse-adapted NC/99 (H1N1). B.
Intracellular cytokine staining of CD8+ HA533-specific pentamer positive lung lymphocytes collected on day 6 post challenge from mice immunized
with TVV, TIV or non-immunized (Mock). C. Percentage of the positive cells in panel B expressing IFN-gamma detected by intracellular cytokine
staining. *represents p,0.05.
doi:10.1371/journal.pone.0006032.g005
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vaccinated with TIV (Fig. 3). To examine cell-mediated memory
responses, we chose to collect splenocytes 6 days post-challenge to
differentiate between primary and memory cellular responses. Even
though CD8+ cytotoxic T cells (CTL) do not prevent infection, T
cells provide some level of protection against influenza by
promoting viral clearance and reducing the severity of symptoms
[21–23]. Influenza-specific CTLs mostly target internal proteins,
such as NP, [24–28] and can provide partial protection across
heterologous strains [29]. VLPs evaluated in the study do not
contain NP and therefore, only TIV-vaccinated mice elicited NP-
specific CD8+ T cells over the background responses induced by
primary viral infection. We cannot rule out that these NP-specific
responses could have aided in the recovery of TIV-vaccinated mice.
The VLPs used in this study induced CD8+ IFN-c secreting cells
that were directed at the HA that were significantly higher than the
inactivated, split TIV indicating that CD8+ T cell responses against
HA may be important in viral clearance. The elicitation of cross-
reactive CD4+ and CD8+ T cell memory responses has been
detected in healthy adults exposed to live influenza virus [29,30].
While we did not directly measure CD4+ specific influenza
responses, and the ELISPOT results presented in this study may
be CD4
+ T cell specific (Fig. 5), previous studies from our group
demonstrated that our influenza VLP vaccines elicit a predomi-
nately IgG2a and IgG2b anti-HA antibodies, indicative of a T-helper
type 1 biased CD4
+ response [10–12].
We expected mice vaccinated with NC/99 VLPs to be
protected against a NC/99 challenge. However, vaccinated mice
lost weight and showed signs of morbidity. Mice are not a natural
host for influenza infection and therefore, viruses need to be
adapted to efficiently replicate in the mouse. During this process,
mutations are introduced. Twelve amino acids were changed in
the HA of the mouse-adapted NC/99 virus and the original
human sequence. Since the vaccine contained the human
sequences, the antibodies elicited recognized the HA sequence
from the human virus, but not the mouse-adapted virus (Fig. 4).
Four of these changes occurred in putative antigenic regions of
HA. Future studies will be needed in order to determine which
mutations are important for this phenomenon. We took advantage
of the mouse-adapted virus to stimulate recall T cell responses
elicited by the VLP vaccine.
Ferrets are generally considered a more relevant animal model
for human influenza infection compared to mice [31]. While cross-
reactive HAI antibodies were detected in mice, there was
Figure 6. Trivalent vs. Monovalent comparison. HAI titers of ferrets vaccinated at the 15 mg dose with (A) trivalent VLP or (B) H3N2 VLP against
a panel of influenza viruses as described in the legend to figure 6.
doi:10.1371/journal.pone.0006032.g006
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particularly at lower doses of VLP vaccine. Interestingly, there was
a dose dependent correlation between the TVV dose and the viral
titer isolated from the nasal wash of NY/04 infected ferrets (Fig. 7).
In addition, viral titers were similar between ferrets vaccinated
with the TVV and the monovalent H3N2 VLP vaccine
administered at the same 15 mg dose, once again indicating that
mixing the VLPs in a trivalent mix did not reduce immunogenic-
ity. We cannot rule out that cellular immune responses played a
role in the protection and fast decline in viral lung titers in TVV-
vaccinated ferrets, since we were not able to measure cellular
responses in ferrets. However, TVV-vaccinated ferrets did have
antibodies that recognized NA that inhibited infection (data not
shown). Humoral immunity elicited by neuraminidase (N1) can
partially protect against H5N1 infection in a mammalian host [32]
and anti-NA (N2) antibodies may have reduced the severity of
disease associated with the antigen shift to H3N2 circulating
viruses in 1968 [33–35]
An advantage of a VLP vaccine approach is a non-infectious
mimicking particle with multiple viral antigens and epitopes that
stimulate a diverse set of immune responses with less
reactogenicity associated with a live-attenuated or whole-
inactivated, split vaccine [10,11]. In general, VLPs have the
potential to activate both endogenous and exogenous antigen
pathways leading to the presentation of viral peptides by MHC
class I and class II molecules [36]. In this study, we showed that
anti-HA specific CD8+ T cells were elicited by a seasonal
influenza VLP vaccine indicating that a multi-epitope vaccine is
more likely than an inactivated, split vaccine to generate a
broad-based immune response. However, it is important to note
that the CD8+ T cell epitopes studied in the mouse model have
not been identified in humans. Particles, unlike single proteins,
have the ability to bind and enter cells using appropriate surface
receptors. These viral proteins can be processed and presented
on MHC class I molecules, therefore promoting presentation to
T-cells by professional antigen presenting cells. In addition, cell-
free VLPs bound with antibodies could be taken up by
phagocytic cells via Fc receptors, thus increasing MHC class
II presentation [36]. Antigens expressed in their native three-
dimensional conformational form can elicit more effective
antibody responses compared to proteins in their non-native
forms [37]. Many neutralizing antibodies directed against viruses
are elicited against conformational epitopes only present in the
native form of envelopes, and some epitopes are only exposed
after binding to receptors during entry. Indeed, both HAI
functional antibody was detected following vaccination with
these VLP vaccines.
In humans, protection and clearance of influenza virus
following infection is not only dependent upon virus virulence,
but also the specific innate immunity, specific serum IgG antibody,
and cell-mediated immunity of the individual infected. Our results
show induction of complementary responses following vaccination
with VLPs – antibodies that block HA binding and CD8+ T cell
responses – that may likely contribute to protection from disease as
demonstrated in the ferret model. In addition to a desirable
immune response, trivalent preparations of VLPs benefit the
public because they can easily be engineered and produced in a
timely fashion, overcoming potential limitations of production of
current egg-based influenza vaccines.
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